In a recent study on MedRxiv, researchers found that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could reduce the risk of severe disease and death.
The study is from St. Michael’s Hospital. One author is Mary Cushman, M.D., M.Sc.
COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly in the lungs, and is believed to contribute to progression to severe disease and death.
Heparin—a blood thinner given regularly at a low dose to hospitalized patients—stops clots from forming and reduces inflammation.
In the study, the team examined the benefits of administering a full dose of heparin to moderately ill patients admitted to hospital wards with COVID-19.
They found that therapeutic heparin didn’t strongly lower incidence of the primary composite of death, mechanical ventilation or ICU admission compared with low dose heparin, the odds of all-cause death were strongly reduced by 78% with heparin.
The researchers also clearly found that therapeutic heparin is beneficial in moderately ill hospitalized COVID-19 patients but not in severely ill ICU patients.
They believe that the findings may result in a change in clinical practice for moderately ill ward patients with COVID-19.
If you care about COVID, please read studies about this stuff in the blood tied to severe COVID-19 and findings of these blood pressure drugs safe for people with severe COVID-19.
For more information about COVID and your health, please see recent studies about scientists find blood vessel damage and inflammation in COVID-19 patients’ brains and results showing that these blood thinning drugs may lower death risk in COVID-19 patients.
Copyright © 2021 Knowridge Science Report. All rights reserved.